When 7-year-old Otto Moriva of Stillwater began limping and reporting knee pain in May 2025, his symptoms initially led to a rheumatology referral. Bloodwork later uncovered B-cell acute lymphoblastic leukemia, and he was diagnosed on June 26, 2025, according to the Minnesota Star Tribune.
Why leukemia can resemble a joint problem
Otto’s initial symptoms fit a documented diagnostic challenge: childhood leukemia can involve the bones, joints and other parts of the musculoskeletal system, making the illness resemble an orthopedic or rheumatologic condition. A study hosted by the National Library of Medicine’s PubMed Central archive says musculoskeletal involvement has been reported in 7.1% to 62.3% of childhood leukemia cases. The wide range reflects differences among studies and patient groups; it is not a precise estimate of how often limping precedes a diagnosis.
A separate 2025 systematic review found musculoskeletal manifestations in 32.1% of children with hematopoietic tumors, but that analysis combined acute lymphoblastic leukemia with acute myeloid leukemia. Its result therefore provides broader context, not a leukemia-specific probability for Otto or for any individual child. Persistent or unexplained symptoms require clinical evaluation, and the research does not establish that most childhood knee pain is caused by cancer.
What is known about Otto’s treatment
The Star Tribune reported that Otto lost the ability to walk independently during intensive treatment and later worked with physical therapists as he regained mobility. The account also said he moved into a maintenance phase, taking chemotherapy at home and attending monthly appointments, after a period of more frequent medical visits. His exact treatment protocol, risk category and medical outlook have not been publicly established.
The National Cancer Institute describes childhood acute lymphoblastic leukemia treatment as a three-phase process. That general framework helps explain why treatment intensity and appointment schedules can change over time, but it does not show which protocol Otto received or allow population-level results to predict his individual course.
The broader picture
Childhood leukemia represents 25.7% of all new childhood cancer cases, according to the National Cancer Institute’s SEER Cancer Stat Facts. Those figures describe groups of patients rather than a single child. The same source cautions that population-based survival statistics cannot predict exactly what will happen to an individual patient because treatments and responses vary.
For Otto, the publicly reported milestones are more specific than any national statistic: after treatment-related loss of mobility, he was reported to be walking again, returning to school and hoping eventually to play soccer. Those details describe one child’s recovery; they should not be treated as evidence of a general trend in childhood leukemia or as a forecast for other patients.
